Early detection is best
Get ahead of cancer when it's most treatable
Finding cancer early creates the best chance for successful treatment.
Only 5 types of cancer have recommended screening tests1
Screening tests look for cancer before symptoms appear. Currently, only 5 types of cancer—colorectal, lung (for those at risk), breast, cervical, and prostate—have recommended screening tests that can identify cancer earlier.1 Most other cancers, like pancreatic and ovarian, do not show symptoms early and are often diagnosed at a later stage.2
When cancer is diagnosed early before it has time to spread, the overall 5-year cancer-specific survival rate is 4 times higher than when cancer is diagnosed late.3
Cancer risk increases with age
More than 1 in 3 people will develop cancer in their lifetime.4
Age is the biggest risk factor for cancer. The risk of cancer increases exponentially after the age of 50. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.5
Cancer risk increases for everyone as they age regardless of family history—only 5% to 10% of cancers are inherited.5,6
Many cancers are often found too late, when symptoms appear in later stages of cancer. The earlier that cancer is diagnosed, the greater the chance of successful treatment and survival.2 The earlier you know, the sooner you can act.
Routine single-cancer screening tests, such as mammography and colonoscopy, save lives.1
However, an individual undergoing single-cancer screening is more likely to be diagnosed with a different cancer than the one being screened.8
Adding a multi-cancer early detection test allows you to go beyond what's currently possible
Get started with the Galleri® test
Healthcare Providers
Healthcare Providers
Healthcare Providers
I am a healthcare provider interested in offering the Galleri test to my patients
Employers
Employers
Employers
I represent an employer interested in offering the Galleri test to my organization’s employees
Health Systems
Health Systems
Health Systems
I represent a health system interested in making the Galleri test available to my patient population
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
US Preventive Services Task Force. Recommendations Cancer. Accessed 7Mar2023. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: 10.3322/caac.21763.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015. Data on file GA-2021-004.
American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes -Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.
NIH/National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. Accessed 3Mar2023. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet.
American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Data on file GA-2021-0065.
Clarke CA, Hubbell E, Ofman JJ. Multi-cancer early detection: A new paradigm for reducing cancer-specific and all-cause mortality. Cancer Cell. 2021 Apr 12;39(4):447-448. DOI: https://doi.org/10.1016/j.ccell.2021.02.004.